Atlas Trials

Excessive Daytime Sleepiness

31 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Excessive Daytime Sleepiness

RecordFirmDate
A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA (NCT05223166)Citrine Medicine Limited2022-04-12
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) (NCT05113745)Axsome Therapeutics, Inc.2021-10-20
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (NCT05059223)Axsome Therapeutics, Inc.2021-09-15
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy (NCT04923594)NLS Pharmaceutics2021-09-13
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 (NCT04886518)Harmony Biosciences Management, Inc.2021-06-28
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (NCT04789174)Axsome Therapeutics, Inc.2021-05-17
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness (NCT03194217)BenevolentAI Bio2017-11-10
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy (NCT02720744)Avadel2016-11-17
Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA (NCT02739568)Bioprojet2016-04-01
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) (NCT01800045)Bioprojet2013-04-01
BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. (NCT01072968)Bioprojet2011-10-01
BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS (NCT01071876)Bioprojet2011-08-01
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) (NCT01620554)Bioprojet2010-10-01
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy (NCT01006122)Pfizer2009-11-01
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy (NCT01067235)Bioprojet2009-10-01
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy (NCT01067222)Bioprojet2009-05-01
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients (NCT00642928)Bioprojet2007-10-01
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome (NCT00228566)Cephalon2005-10-01
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness (NCT00228553)Cephalon2004-05-01
Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder (NCT00385437)University Health Network, Toronto2003-04-01
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness (NCT02978651)Bioprojet

Track Excessive Daytime Sleepiness automatically

Every clearance here is in the API, with alerts when new ones post.